CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Blink® Tears eye drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06131476
NCT06131476Phase 1Completed

Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop

Johnson & Johnson Vision Care, Inc.·interventional·Posted Nov 14, 2023·Updated Jun 26, 2024

In Brief

A Phase 1 clinical trial evaluating Blink® Tears eye drops and Investigational lipid eye drops for Visual Acuity. Completed, enrolled 32 participants across 2 sites.

Detailed Summary

This is a single visit, randomized, double masked, bilateral, non-dispensing, 2×2 crossover study to assess visual acuity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVisual Acuity
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedNov 14, 2023
Enrollment StartSep 16, 2020
Primary CompletionOct 10, 2020
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 2.6 years ago

Interventions

Blink® Tears eye dropsdrug

Control Drops

Investigational lipid eye dropsdrug

Test Drops